<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on May 29, 2018</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03448445</url>
  </required_header>
  <id_info>
    <org_study_id>E0000-M082-603</org_study_id>
    <nct_id>NCT03448445</nct_id>
  </id_info>
  <brief_title>A Study to Evaluate Alzheimer's Disease Conversion Rate Differences Between High-risk Mild Cognitive Impairment (MCI) and Low-risk MCI in a Real World Setting</brief_title>
  <acronym>CONCORDE</acronym>
  <official_title>An Observational Study to Evaluate AD Conversion Rate Differences Between High-risk MCI and Low Risk MCI in Real World Setting</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Eisai Korea Inc.</agency>
      <agency_class>Industry</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Eisai Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study will be conducted to evaluate the rate of Alzheimer's disease conversion
      differences between high-risk mild cognitive impairment (MCI) and low-risk MCI.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 22, 2018</start_date>
  <completion_date type="Anticipated">December 23, 2020</completion_date>
  <primary_completion_date type="Anticipated">December 23, 2020</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Rate of Alzheimer's Disease (AD) conversion differences between high-risk mild cognitive impairment (MCI) and low-risk MCI</measure>
    <time_frame>Up to 36 months</time_frame>
    <description>AD conversion differences will be assessed according to National Institute of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related Disorders Association Criteria for Probable AD.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in Seoul Neuropsychological Screening Battery-Dementia Version scores</measure>
    <time_frame>Baseline, Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in Clinical Dementia Rating (CDR) Sum of Boxes scores</measure>
    <time_frame>Baseline, Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the CDR-Global Score</measure>
    <time_frame>Baseline, Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in Geriatric Depression Scale scores</measure>
    <time_frame>Baseline, Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the volume of the whole brain according to Baseline demographics</measure>
    <time_frame>Baseline, Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in other structural magnetic resonance imaging (MRI) measures according to Baseline demographics</measure>
    <time_frame>Baseline, Month 12, Month 24</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Mean change from Baseline in the volume of the hippocampus according to Baseline demographics</measure>
    <time_frame>Baseline, Month 12, Month 24</time_frame>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Mild Cognitive Impairment</condition>
  <arm_group>
    <arm_group_label>High-risk MCI</arm_group_label>
    <description>This cohort will include participants with high-risk mild cognitive impairment (MCI).</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Low-risk MCI</arm_group_label>
    <description>This cohort will include participants with low-risk MCI.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Usual care setting</intervention_name>
    <description>usual care settings without any intervention</description>
    <arm_group_label>High-risk MCI</arm_group_label>
    <arm_group_label>Low-risk MCI</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Participants with mild cognitive impairment
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Participant over 55 years old and less than 90 years old

          -  Participant with subjective memory complaint by informant

          -  Clinical Dementia Rating (CDR) of 0.5; memory score box must be at least 0.5

          -  General cognition and functional performance sufficiently preserved such that a
             diagnosis of Alzheimer's disease cannot be made by the site physician at the time of
             the screening visit

          -  Essentially preserved activities of daily living

          -  Absence of dementia

          -  Participant with Seoul Neuropsychological Screening Battery-Dementia Version cut-off
             score between 134.25 and 188.25

          -  Participants and caregivers who give written authorization to use their personal and
             health data

          -  Cognitive decline history within past 6 months from the baseline

        Exclusion Criteria:

          -  Diagnostic evidence of probable Alzheimer's disease consistent with National Institute
             of Neurological and Communicative Diseases and Stroke-Alzheimer's Disease and Related
             Disorders Association

          -  CDR-Global score (CDR-GS) &gt;1

          -  Participant who has taken memantine, acetylcholinesterase inhibitors, or nootropics
             prior to participating in this study

          -  Any significant neurologic disease: other than suspected incipient Alzheimer's
             disease, such as Parkinson's disease, multi-infarct dementia, Huntington's disease,
             normal pressure hydrocephalus, brain tumor, progressive supranuclear palsy, seizure
             disorder, subdural hematoma, multiple sclerosis, or history of significant head trauma
             followed by persistent neurologic defaults or known structural brain abnormalities

          -  Neuroimaging: participant with severe subcortical hyperintensities: D3-P3

          -  Magnetic resonance imaging exclusions: presence of pacemakers, aneurysm clips,
             artificial heart valves, ear implants, metal fragments or foreign objects in the eyes,
             skin or body

          -  Participant who is pregnant, lactating or of childbearing potential (i.e., women must
             be two years post-menopausal or surgically sterile)
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>55 Years</minimum_age>
    <maximum_age>89 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_contact>
    <last_name>Haejoon Park</last_name>
    <phone>+82-2-3451-5539</phone>
    <email>h3-park@eisaikorea.com</email>
  </overall_contact>
  <location>
    <facility>
      <name>Eisai Trial site_12</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_11</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_15</name>
      <address>
        <city>Busan</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_08</name>
      <address>
        <city>Changwon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_09</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_05</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_03</name>
      <address>
        <city>Gachon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_07</name>
      <address>
        <city>Guri</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_10</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_16</name>
      <address>
        <city>Jeju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_01</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_02</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_04</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_06</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_13</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location>
    <facility>
      <name>Eisai Trial site_14</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
    <status>Not yet recruiting</status>
  </location>
  <location_countries>
    <country>Korea, Republic of</country>
  </location_countries>
  <verification_date>May 2018</verification_date>
  <!-- For several months we've had both old and new date name tags                             -->
  <!-- Now, the old date names have been dropped.                                               -->
  <!-- The new date name replacements are:                                                      -->
  <!--     OLD (gone)                                        NEW (in use)                       -->
  <!--   lastchanged_date                         becomes   last_update_submitted               -->
  <!--   firstreceived_date                       becomes   study_first_submitted               -->
  <!--   firstreceived_results_date               becomes   results_first_submitted             -->
  <!--   firstreceived_results_disposition_date   becomes   disposition_first_submitted         -->
  <study_first_submitted>February 22, 2018</study_first_submitted>
  <study_first_submitted_qc>February 22, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">February 28, 2018</study_first_posted>
  <last_update_submitted>May 21, 2018</last_update_submitted>
  <last_update_submitted_qc>May 21, 2018</last_update_submitted_qc>
  <last_update_posted type="Actual">May 22, 2018</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>High-risk</keyword>
  <keyword>Low-risk</keyword>
  <keyword>Alzheimer's disease</keyword>
  <keyword>Observational study</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Alzheimer Disease</mesh_term>
    <mesh_term>Cognitive Dysfunction</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

